secwatch.observer — SEC 8-K summary
======================================

Issuer:     MBX Biosciences, Inc. (MBX)
CIK:        0001776111
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-122824
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MBX Biosciences Q3 net loss $18.1M; cash $277M funds into mid-2027; IPO raised $251M
--------------------------------------------------------------------------------

- Net loss for Q3 2024 was $18.1M vs $10.2M in Q3 2023; R&D spend rose to $16.7M from $9.1M.
- Cash, equivalents and marketable securities $277.1M as of Sep 30, 2024 (up from $80.7M at Dec 31, 2023).
- IPO and Series C gross proceeds totaled approximately $251.2M.
- Phase 1 trial of MBX 1416 (post-bariatric hypoglycemia) last subject visit by late Nov 2024; topline results early Jan 2025.
- Phase 2 Avail trial of MBX 2109 (hypoparathyroidism) enrollment completion expected Q1 2025; topline results Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1776111/000095017024122824/0000950170-24-122824-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1776111/000095017024122824/mbx-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122824

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer